Lineage Cell Therapeutics Reports Q2 2026 Financial Results

What Happened

• Lineage Cell Therapeutics, Inc. (LCTX) filed a Form 8-K on August 6, 2026 to report its financial results for the quarter ended June 30, 2026. The company furnished a press release announcing those quarterly results as Exhibit 99.1 to the filing.

Key Details

• Filing date: August 6, 2026 (Form 8-K Items 2.02 and 9.01).
• Reporting period: quarter ended June 30, 2026.
• Press release: furnished as Exhibit 99.1 (text of financial results and commentary is in that exhibit).
• Signature: filing signed by George A. Samuel III, General Counsel and Corporate Secretary.

Why It Matters

• Quarterly earnings announcements provide investors with updated information on revenue, expenses, and operational performance; this 8-K signals that LCTX has published those updates and related management commentary in the attached press release.
• The Form 8-K itself does not include the financial line items — investors should review Exhibit 99.1 (the press release) and any subsequent filings (e.g., 10-Q) for the full financial details, metrics, and management discussion before making investment decisions.